Biswas, S., Srivastava, Y., Hamadttu, A. (2026). Real-world comparison of cabozantinib versus regorafenib as second-line therapy for advanced hepatocellular carcinoma after first-line immune checkpoint inhibitors: A propensity score–matched analysis.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.19_suppl.132